The Council of Scientific and Industrial Research, Department of Science and Technology, and Department of Biotechnology will work with Indian Council of Medical Research (ICMR) to further the agenda of the development of a vaccine for coronavirus, said R Gangakhedkar, head, Epidemiology and Communicable Diseases Division of ICMR.
"CSIR, Department of Science and Technology, and Department of Biotechnology will work with the ICMR to further the agenda of the development of a vaccine for COVID-19," Gangakhedkar said at a press conference here on Tuesday.
Speaking on whether the country has the capacity to conduct tests for an increasing number of suspected coronavirus patients, he said, "Till now we have tested 42,788 samples, including 4,346 samples that were tested on March 30. It represents 36 per cent of our capacity.
"123 labs have been made functional, 49 private labs have been given permission. Yesterday 399 patients were tested in private labs," he added.
Meanwhile, Lav Aggarwal, Joint Secretary, Ministry of Health and Family Welfare, said that till now a total of 1,251 cases and 32 deaths have been reported in the country.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
